SK112996A3 - Firoblast growth factor-10 - Google Patents

Firoblast growth factor-10 Download PDF

Info

Publication number: SK112996A3
Authority: SK; Slovakia
Prior art keywords: polypeptide; fgf; dna; polynucleotide; sequence
Prior art date: 1994-03-08

Application number

SK1129-96A

Other languages

English (en)

Slovak (sk)

Inventor

Jing-Shan Hu

Jeannine Gocayne

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-08

Filing date

1995-03-08

Publication date

1997-01-08

1995-03-08 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

1997-01-08 Publication of SK112996A3 publication Critical patent/SK112996A3/sk

Links

230000012010 growth Effects 0.000 title description 8
108010014173 Factor X Proteins 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 139
229920001184 polypeptide Polymers 0.000 claims abstract description 134
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 134
108090001047 Fibroblast growth factor 10 Proteins 0.000 claims abstract description 88
102100028412 Fibroblast growth factor 10 Human genes 0.000 claims abstract description 84
238000000034 method Methods 0.000 claims abstract description 46
108020004414 DNA Proteins 0.000 claims abstract description 45
108091026890 Coding region Proteins 0.000 claims abstract description 21
239000005557 antagonist Substances 0.000 claims abstract description 18
230000035772 mutation Effects 0.000 claims abstract description 10
230000004663 cell proliferation Effects 0.000 claims abstract description 6
108091033319 polynucleotide Proteins 0.000 claims description 54
102000040430 polynucleotide Human genes 0.000 claims description 54
239000002157 polynucleotide Substances 0.000 claims description 54
239000002299 complementary DNA Substances 0.000 claims description 43
239000013598 vector Substances 0.000 claims description 38
239000012634 fragment Substances 0.000 claims description 29
230000014509 gene expression Effects 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
125000003275 alpha amino acid group Chemical group 0.000 claims description 17
201000010099 disease Diseases 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 16
150000007523 nucleic acids Chemical group 0.000 claims description 16
108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
238000001727 in vivo Methods 0.000 claims description 11
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
239000000556 agonist Substances 0.000 claims description 7
239000011541 reaction mixture Substances 0.000 claims description 5
230000000694 effects Effects 0.000 claims description 3
238000003745 diagnosis Methods 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims 1
101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 abstract description 4
208000027418 Wounds and injury Diseases 0.000 abstract description 4
238000010188 recombinant method Methods 0.000 abstract description 4
230000001225 therapeutic effect Effects 0.000 abstract description 4
206010052428 Wound Diseases 0.000 abstract description 3
102000057243 human FGF10 Human genes 0.000 abstract description 3
230000003961 neuronal insult Effects 0.000 abstract description 3
230000002159 abnormal effect Effects 0.000 abstract description 2
230000000250 revascularization Effects 0.000 abstract description 2
230000004936 stimulating effect Effects 0.000 abstract description 2
230000004075 alteration Effects 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
210000003644 lens cell Anatomy 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 49
108090000623 proteins and genes Proteins 0.000 description 48
102000004169 proteins and genes Human genes 0.000 description 25
239000013615 primer Substances 0.000 description 23
239000000047 product Substances 0.000 description 16
210000001519 tissue Anatomy 0.000 description 15
101150021185 FGF gene Proteins 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 14
239000013612 plasmid Substances 0.000 description 14
210000000349 chromosome Anatomy 0.000 description 13
239000000523 sample Substances 0.000 description 12
238000003556 assay Methods 0.000 description 11
102000039446 nucleic acids Human genes 0.000 description 11
108020004707 nucleic acids Proteins 0.000 description 11
238000013518 transcription Methods 0.000 description 11
230000035897 transcription Effects 0.000 description 11
230000001580 bacterial effect Effects 0.000 description 10
230000027455 binding Effects 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
108020004999 messenger RNA Proteins 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 9
238000013519 translation Methods 0.000 description 9
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 8
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 8
210000002950 fibroblast Anatomy 0.000 description 8
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
239000003623 enhancer Substances 0.000 description 7
230000002068 genetic effect Effects 0.000 description 7
108050007372 Fibroblast Growth Factor Proteins 0.000 description 6
230000000692 anti-sense effect Effects 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
239000000835 fiber Substances 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000003550 marker Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000010076 replication Effects 0.000 description 6
238000012216 screening Methods 0.000 description 6
239000007787 solid Substances 0.000 description 6
102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
230000006870 function Effects 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 4
101710154606 Hemagglutinin Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
101710176177 Protein A56 Proteins 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
230000002759 chromosomal effect Effects 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
238000013507 mapping Methods 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108020004491 Antisense DNA Proteins 0.000 description 3
108020005544 Antisense RNA Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000033115 angiogenesis Effects 0.000 description 3
239000003816 antisense DNA Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
239000000185 hemagglutinin Substances 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
210000002752 melanocyte Anatomy 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
229960004452 methionine Drugs 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
210000003556 vascular endothelial cell Anatomy 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
201000004384 Alopecia Diseases 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
210000000695 crystalline len Anatomy 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
208000024963 hair loss Diseases 0.000 description 2
230000003676 hair loss Effects 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
210000002510 keratinocyte Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000003716 mesoderm Anatomy 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
210000001995 reticulocyte Anatomy 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
210000002363 skeletal muscle cell Anatomy 0.000 description 2
230000009759 skin aging Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
101100238293 Arabidopsis thaliana MOR1 gene Proteins 0.000 description 1
OLDOLPWZEMHNIA-PJODQICGSA-N Arg-Ala-Trp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OLDOLPWZEMHNIA-PJODQICGSA-N 0.000 description 1
NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
101001051969 Bos taurus Fibroblast growth factor 2 Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
CYHMMWIOEUVHHZ-IHRRRGAJSA-N Cys-Met-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CYHMMWIOEUVHHZ-IHRRRGAJSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
108090000367 Fibroblast growth factor 9 Proteins 0.000 description 1
102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
ISXJHXGYMJKXOI-GUBZILKMSA-N Glu-Cys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O ISXJHXGYMJKXOI-GUBZILKMSA-N 0.000 description 1
RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 1
XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 1
OCRQUYDOYKCOQG-IRXDYDNUSA-N Gly-Tyr-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 OCRQUYDOYKCOQG-IRXDYDNUSA-N 0.000 description 1
108010078321 Guanylate Cyclase Proteins 0.000 description 1
102000014469 Guanylate cyclase Human genes 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
KTGFOCFYOZQVRJ-ZKWXMUAHSA-N Ile-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O KTGFOCFYOZQVRJ-ZKWXMUAHSA-N 0.000 description 1
LPFBXFILACZHIB-LAEOZQHASA-N Ile-Gly-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)N LPFBXFILACZHIB-LAEOZQHASA-N 0.000 description 1
ZUPJCJINYQISSN-XUXIUFHCSA-N Ile-Met-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUPJCJINYQISSN-XUXIUFHCSA-N 0.000 description 1
ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
KXODZBLFVFSLAI-AVGNSLFASA-N Leu-His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 KXODZBLFVFSLAI-AVGNSLFASA-N 0.000 description 1
LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
241001460678 Napo <wasp> Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
WLYPRKLMRIYGPP-JYJNAYRXSA-N Phe-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 WLYPRKLMRIYGPP-JYJNAYRXSA-N 0.000 description 1
ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 1
NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 1
HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 1
YZMPDHTZJJCGEI-BQBZGAKWSA-N Ser-His Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 YZMPDHTZJJCGEI-BQBZGAKWSA-N 0.000 description 1
NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
101150006914 TRP1 gene Proteins 0.000 description 1
PRNGXSILMXSWQQ-OEAJRASXSA-N Thr-Leu-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PRNGXSILMXSWQQ-OEAJRASXSA-N 0.000 description 1
ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 1
JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
108010013835 arginine glutamate Proteins 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
238000013475 authorization Methods 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
ZWPRYVATYZPCDP-UHFFFAOYSA-M bis(dibutylamino)methylidene-dibutylazanium;fluoride Chemical compound [F-].CCCCN(CCCC)C(N(CCCC)CCCC)=[N+](CCCC)CCCC ZWPRYVATYZPCDP-UHFFFAOYSA-M 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
238000003200 chromosome mapping Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000000399 corneal endothelial cell Anatomy 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000011243 crosslinked material Substances 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
101150056310 gem1 gene Proteins 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
108010037389 glutamyl-cysteinyl-lysine Proteins 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
108010087823 glycyltyrosine Proteins 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000002768 hair cell Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000010249 in-situ analysis Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
108010053037 kyotorphin Proteins 0.000 description 1
238000002372 labelling Methods 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
108010051242 phenylalanylserine Proteins 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
150000003906 phosphoinositides Chemical class 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
-1 polyethylene glycol) Chemical class 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000030788 protein refolding Effects 0.000 description 1
208000009305 pseudorabies Diseases 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
108010048818 seryl-histidine Proteins 0.000 description 1
238000004513 sizing Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
108010003137 tyrosyltyrosine Proteins 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
108010027345 wheylin-1 peptide Proteins 0.000 description 1
108010000998 wheylin-2 peptide Proteins 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1129-96A 1994-03-08 1995-03-08 Firoblast growth factor-10 SK112996A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/207,412 US5817485A (en)	1994-03-08	1994-03-08	Nucleic acids and cells for recombinant production of fibroblast growth factor-10
PCT/US1995/002950 WO1995024414A1 (fr)	1994-03-08	1995-03-08	Facteur-10 de croissance du fibroblaste

Publications (1)

Publication Number	Publication Date
SK112996A3 true SK112996A3 (en)	1997-01-08

Family

ID=22770445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1129-96A SK112996A3 (en)	1994-03-08	1995-03-08	Firoblast growth factor-10

Country Status (21)

Country	Link
US (2)	US5817485A (fr)
EP (2)	EP1380594A1 (fr)
JP (2)	JPH09510103A (fr)
CN (1)	CN1150804A (fr)
AT (1)	ATE251637T1 (fr)
AU (1)	AU1986195A (fr)
CA (1)	CA2183961A1 (fr)
CZ (1)	CZ260696A3 (fr)
DE (1)	DE69531892T2 (fr)
DK (1)	DK0750628T3 (fr)
ES (1)	ES2208676T3 (fr)
FI (1)	FI963475A (fr)
HU (1)	HUT77578A (fr)
IL (1)	IL112878A0 (fr)
MX (1)	MX9603897A (fr)
NO (1)	NO963728L (fr)
PL (1)	PL316202A1 (fr)
PT (1)	PT750628E (fr)
SK (1)	SK112996A3 (fr)
WO (1)	WO1995024414A1 (fr)
ZA (1)	ZA951886B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6734285B2 (en)	1994-03-08	2004-05-11	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en)	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en)	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en)	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7153827B1 (en)	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
ATE309360T1 (de)	1994-03-08	2005-11-15	Human Genome Sciences Inc	Vaskularer endothelialer wachstumsfaktor 2
US6040157A (en)	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US5693775A (en) *	1995-05-12	1997-12-02	The Johns Hopkins University School Of Medicine	Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
EP0832216A4 (fr) *	1995-06-05	1999-06-16	Human Genome Sciences Inc	Facteur 15 de croissance des fibroblastes
US5773252A (en)	1995-06-05	1998-06-30	Human Genome Sciences, Inc.	Fibroblast growth factor 15
US6020189A (en) *	1996-08-30	2000-02-01	The Johns Hopkins University School Of Medicine	Fibroblast growth factor homologous factors (FHFs) and methods of use
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
JPH10279501A (ja) *	1997-02-10	1998-10-20	Rohto Pharmaceut Co Ltd	育毛剤
US6335317B1 (en) *	1998-04-10	2002-01-01	Emory University	Use of gut-trophic growth factors to improve oxidative status
US7223724B1 (en)	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
AU5440800A (en) *	1999-05-21	2000-12-12	Human Genome Sciences, Inc.	Fibroblast growth factor 10
CA2407910C (fr)	2000-06-16	2013-03-12	Steven M. Ruben	Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
NZ518077A (en)	2000-08-04	2003-11-28	Human Genome Sciences Inc	Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US20030091565A1 (en)	2000-08-18	2003-05-15	Beltzer James P.	Binding polypeptides and methods based thereon
US7402312B2 (en)	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
WO2002083704A1 (fr)	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Facteur de croissance 2, endothelial, vasculaire
US20060183712A1 (en) *	2005-02-17	2006-08-17	The Texas A&M University System	Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
KR101187871B1 (ko)	2009-09-23	2012-10-05	(주)케어젠	Ｆｇｆ１０－유래 펩타이드 및 그의 용도
CA2808644A1 (fr) *	2010-11-23	2012-05-31	Kci Licensing Inc.	Dispositifs et procedes pour le diagnostic et le traitement de blessures a l'aide de biomarqueurs
CN103169658A (zh) *	2012-10-26	2013-06-26	温州医学院	成纤维细胞生长因子-10脂质体制备及在毛发再生中的应用
EP4183796A1 (fr)	2021-11-19	2023-05-24	Enantis s.r.o.	Polypeptide ou fragment fgf10 thermostable et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5155214A (en) *	1984-03-05	1992-10-13	The Salk Institute For Biological Studies	Basic fibroblast growth factor
US4868113A (en) *	1986-03-03	1989-09-19	Rorer Biotechnology, Inc.	Recombinant DNA vector encoding human endothelial cell growth factor
JP3303211B2 (ja) *	1991-04-26	2002-07-15	武田薬品工業株式会社	ｂＦＧＦムテインおよびその製造法
AU4995193A (en) *	1992-08-04	1994-03-03	Regeneron Pharmaceuticals, Inc.	Method of enhancing differentiation and survival of neuronal precursor cells

1994
- 1994-03-08 US US08/207,412 patent/US5817485A/en not_active Expired - Fee Related
1995
- 1995-03-03 IL IL11287895A patent/IL112878A0/xx unknown
- 1995-03-07 ZA ZA951886A patent/ZA951886B/xx unknown
- 1995-03-08 MX MX9603897A patent/MX9603897A/es unknown
- 1995-03-08 DK DK95912829T patent/DK0750628T3/da active
- 1995-03-08 PL PL95316202A patent/PL316202A1/xx unknown
- 1995-03-08 AU AU19861/95A patent/AU1986195A/en not_active Abandoned
- 1995-03-08 CA CA002183961A patent/CA2183961A1/fr not_active Abandoned
- 1995-03-08 CN CN95192340A patent/CN1150804A/zh active Pending
- 1995-03-08 EP EP03022286A patent/EP1380594A1/fr not_active Withdrawn
- 1995-03-08 SK SK1129-96A patent/SK112996A3/sk unknown
- 1995-03-08 HU HU9602434A patent/HUT77578A/hu unknown
- 1995-03-08 JP JP7523645A patent/JPH09510103A/ja not_active Ceased
- 1995-03-08 PT PT95912829T patent/PT750628E/pt unknown
- 1995-03-08 DE DE69531892T patent/DE69531892T2/de not_active Expired - Fee Related
- 1995-03-08 ES ES95912829T patent/ES2208676T3/es not_active Expired - Lifetime
- 1995-03-08 CZ CZ962606A patent/CZ260696A3/cs unknown
- 1995-03-08 WO PCT/US1995/002950 patent/WO1995024414A1/fr active IP Right Grant
- 1995-03-08 AT AT95912829T patent/ATE251637T1/de not_active IP Right Cessation
- 1995-03-08 EP EP95912829A patent/EP0750628B1/fr not_active Expired - Lifetime
1996
- 1996-09-05 FI FI963475A patent/FI963475A/fi not_active Application Discontinuation
- 1996-09-06 NO NO963728A patent/NO963728L/no unknown
2001
- 2001-07-12 US US09/902,773 patent/US20020034787A1/en not_active Abandoned
2002
- 2002-03-05 JP JP2002058893A patent/JP2002335982A/ja active Pending

Also Published As

Publication number	Publication date
ATE251637T1 (de)	2003-10-15
HU9602434D0 (en)	1996-11-28
IL112878A0 (en)	1995-06-29
EP0750628B1 (fr)	2003-10-08
US20020034787A1 (en)	2002-03-21
WO1995024414A1 (fr)	1995-09-14
ZA951886B (en)	1996-09-09
FI963475A0 (fi)	1996-09-05
NO963728D0 (no)	1996-09-06
AU1986195A (en)	1995-09-25
DE69531892D1 (de)	2003-11-13
JP2002335982A (ja)	2002-11-26
EP0750628A4 (fr)	1997-06-11
PL316202A1 (en)	1996-12-23
EP0750628A1 (fr)	1997-01-02
CN1150804A (zh)	1997-05-28
EP1380594A1 (fr)	2004-01-14
HUT77578A (hu)	1998-06-29
PT750628E (pt)	2004-03-31
CZ260696A3 (en)	1997-05-14
DE69531892T2 (de)	2004-07-22
ES2208676T3 (es)	2004-06-16
JPH09510103A (ja)	1997-10-14
US5817485A (en)	1998-10-06
CA2183961A1 (fr)	1995-09-14
NO963728L (no)	1996-11-07
DK0750628T3 (da)	2004-02-02
MX9603897A (es)	1997-07-31
FI963475A (fi)	1996-11-05

Publication	Publication Date	Title
SK112996A3 (en)	1997-01-08	Firoblast growth factor-10
JP4439490B2 (ja)	2010-03-24	血管内皮細胞増殖因子２
US7741055B2 (en)	2010-06-22	Prostatic growth factor
US6521227B1 (en)	2003-02-18	Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
NZ269871A (en)	1998-03-25	Haemopoietic maturation factor and coding sequences
JP2002300893A (ja)	2002-10-15	ヒト成長ホルモン
WO1996018730A1 (fr)	1996-06-20	Facteur de croissance prostatique
US5858705A (en)	1999-01-12	Polynucleotides encoding human DNA ligase III and methods of using these polynucleotides
US6639052B1 (en)	2003-10-28	Human ADA2 polypeptides
US6358702B1 (en)	2002-03-19	Polynucleotides encoding human Hox C10
US6573360B1 (en)	2003-06-03	Human ABH
KR19990008319A (ko)	1999-01-25	섬유아세포 성장 인자 15
JPH10201491A (ja)	1998-08-04	タンパク質ホスファターゼ１結合タンパク質ｒ５
MXPA96003897A (en)		Factor 10 of fibroblas growth
WO1996011259A1 (fr)	1996-04-18	ACTIVINE 1 ET ACTIVINE 3, DE LA FAMILLE DES RECEPTEURS DU FACTEUR TRANSFORMANT DE CROISSANCE TGF-β1
JPH1132782A (ja)	1999-02-09	Ｙｎｌ０７５ｗ／ｈｔｘｆｔ１９ポリヌクレオチドおよびポリペプチド
JPH1132783A (ja)	1999-02-09	Ｈｆｉｚｇ５３ポリヌクレオチドおよびポリペプチド
JP2002325590A (ja)	2002-11-12	ケラチノサイト増殖因子−２
AU2005200547A1 (en)	2005-03-10	Vascular Endothelial Growth Factor 2
CA2430223A1 (fr)	1996-08-22	Facteur-2 de croissance des keratinocytes
MXPA97008493A (en)	1998-01-01	Factor 15 of fibroblas growth
AU1247800A (en)	2000-04-20	Fibroblast growth factor 15